veristat Infographics
-
Enhancing Trial Efficiency With Thoughtful Database Design
2/17/2023
Better understand the key considerations that should be discussed prior to designing a clinical trial database, all of which can impact the efficiency of the clinical program.
-
Autologous Vs. Allogeneic Cell And Gene Therapies
1/17/2023
There are two types of cell therapies in development: autologous and allogeneic. Each provides distinct clinical and production advantages and challenges, and therapeutic capabilities.
-
Shortening Development And Approval Timelines For Medicinal Products
12/7/2022
Discover a strategic regulatory plan and leverage the right pathways to drive faster and more efficient drug development.
-
Lessons Learned For Better Planning Of Decentralized Clinical Trials
9/9/2022
Planning a decentralized clinical trial brings with it new challenges to overcome. Learn how to navigate this novel approach designed with a custom virtual ecosystem to satisfy both study and patient needs.
-
Similarities And Differences Between The CTA And IND
9/9/2022
Utilize this infographic when considering the purpose, content, and procedural similarities and differences between the Clinical Trial Authorization and Investigational New Drug Application.
-
When And Why To Hold A Pre-IND Meeting With FDA
9/9/2022
While a pre-IND meeting with the FDA is optional, discover why it is recommended that all drug developers planning to submit an IND to the FDA have one.
-
Guidelines For Response Criteria For Use In Oncology Trials
5/31/2022
Maintain consistency at sites and across sites, as well as limit any site bias, by using Response Evaluation Criteria in Solid Tumors (RECIST) when evaluating tumor response.
-
What Is An IND And Why Do I Need One?
8/30/2021
This infographic explores the purpose of the IND, their types, the format, what the FDA really cares about, and how the applications are approved by the FDA.
-
The DCT Continuum: Finding The Right Model And Right Fit For Small And Mid-Size Sponsors
7/14/2021
The clinical trial landscape is continually adapting its focus on patient-centric practices to improve clinical trial participation by reducing patients’ burden. By leveraging virtual trial tools and strategies, you can support a patient-centric approach and continue to deliver efficient and superior quality clinical trials.
-
FDA Meeting Types: Timing, Purpose & Examples Of Type A, B & C Meetings With CDER And CBER
4/27/2021
Meeting with the FDA to discuss your development plans can help reduce both costs and time to approval. To meet with the FDA, you will need to decide on your preferred format for the meeting and submit a formal meeting request accompanied with or followed closely by an informational package. View our FDA Meeting Types Infographic to learn about Type A, Type B and Type C meetings – with specific insights into meeting timing, purposes and examples of each type throughout development.